Citigroup
REVB icon

Citigroup’s Revelation Biosciences REVB Stock Holding History

Citigroup’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Hold
0
– -$1 – 6397
2025
Q3 		– Hold
0
– – – 6042
2022
Q3 		– Sell
-1
Closed -$287K – 6239
2022
Q2 		$287K Buy
+1
New +$148K ﹤0.01% 3632
2022
Q1 		– Hold
0
– – – 6088

Other funds holding REVB

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Citigroup's REVB Position: Q4 2025 in Review

Citigroup held its Revelation Biosciences (REVB) position steady in Q4 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #6397.

Citigroup first reported a position in REVB in Q2 2022 and has held it in 1 quarter since. The position peaked at $287K in Q2 2022. 13 funds tracked by Wall St. Rank hold REVB as of Q4 2025.

  • Citigroup held 0 shares of Revelation Biosciences worth $0 as of Q4 2025.
  • Citigroup left its Revelation Biosciences share count unchanged in Q4 2025.
  • Revelation Biosciences made up ﹤0.01% of Citigroup's portfolio in Q4 2025, its #6397 holding.
  • Citigroup first reported a position in Revelation Biosciences in Q2 2022 and has held it in 1 quarter since.
  • Citigroup's Revelation Biosciences position peaked at $287K in Q2 2022.
  • 13 funds tracked by Wall St. Rank held Revelation Biosciences as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.